Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecol Oncol. 2017 12; 147(3):509-513.
View in:
PubMed
subject areas
Age Factors
Age Factors
Aged
Aged
Clinical Trials, Phase I as Topic
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase II as Topic
Female
Female
Humans
Humans
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Neoplasms, Glandular and Epithelial
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Ovarian Neoplasms
Phthalazines
Phthalazines
Piperazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
Prospective Studies
Prospective Studies
Randomized Controlled Trials as Topic
Randomized Controlled Trials as Topic
authors with profiles
Kai Ding
Lauren E Dockery